Generation Bio Co. GBIO,
set terms for its planned initial public offering on Monday, with plans
to offer 7.4 million shares priced at $16 to $18 each. The company
would raise $133.2 million at the top end of that range. The company has
applied to list on Nasdaq, under the ticker symbol “GBIO.” J.P. Morgan,
Jefferies, Cowen and Wedbush PacGrow are underwriting the deal.
Proceeds will be used to fund R&D, to develop platform technologies
and for general corporate purposes. “We are an innovative genetic
medicines company creating a new class of gene therapy utilizing our
proprietary non-viral gene therapy platform to provide durable,
redosable treatments for millions of patients living with rare and
prevalent diseases,” the company says in its prospectus.
https://www.marketwatch.com/story/generation-bio-to-offer-74-million-shares-in-planned-ipo-priced-at-16-to-18-each-2020-06-08
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.